Handelsbanken Fonder AB Acquires 28,192 Shares of Intuitive Surgical, Inc. $ISRG

Handelsbanken Fonder AB increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 315,981 shares of the medical equipment provider’s stock after purchasing an additional 28,192 shares during the quarter. Handelsbanken Fonder AB owned 0.09% of Intuitive Surgical worth $141,316,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Intuitive Surgical during the 2nd quarter valued at about $2,569,260,000. Rakuten Investment Management Inc. bought a new position in Intuitive Surgical during the third quarter valued at approximately $388,436,000. Vanguard Group Inc. lifted its position in Intuitive Surgical by 2.1% during the second quarter. Vanguard Group Inc. now owns 33,335,833 shares of the medical equipment provider’s stock valued at $18,115,025,000 after purchasing an additional 670,302 shares during the period. Canada Pension Plan Investment Board boosted its holdings in Intuitive Surgical by 27.1% in the second quarter. Canada Pension Plan Investment Board now owns 1,089,293 shares of the medical equipment provider’s stock worth $591,933,000 after purchasing an additional 231,980 shares during the last quarter. Finally, Winslow Capital Management LLC grew its position in Intuitive Surgical by 20.2% in the 2nd quarter. Winslow Capital Management LLC now owns 1,342,473 shares of the medical equipment provider’s stock worth $729,513,000 after purchasing an additional 225,545 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Barclays set a $712.00 price target on Intuitive Surgical and gave the stock an “overweight” rating in a research note on Monday, January 26th. Royal Bank Of Canada raised their target price on Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Wells Fargo & Company boosted their price target on Intuitive Surgical from $600.00 to $654.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Robert W. Baird lowered their price objective on shares of Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Finally, Raymond James Financial raised their price objective on shares of Intuitive Surgical from $603.00 to $615.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $615.86.

Insider Activity

In other news, Director Gary S. Guthart sold 2,800 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $531.52, for a total transaction of $1,488,256.00. Following the sale, the director directly owned 15,720 shares in the company, valued at $8,355,494.40. This trade represents a 15.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark Brosius sold 464 shares of Intuitive Surgical stock in a transaction on Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the transaction, the senior vice president owned 131 shares in the company, valued at approximately $71,852.19. This trade represents a 77.98% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 56,189 shares of company stock valued at $30,785,441. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Up 0.1%

NASDAQ ISRG opened at $506.88 on Friday. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $603.88. The company has a market capitalization of $180.01 billion, a P/E ratio of 64.24, a price-to-earnings-growth ratio of 3.90 and a beta of 1.65. The stock’s 50-day moving average price is $531.21 and its 200-day moving average price is $511.26.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The company had revenue of $2.87 billion during the quarter, compared to analyst estimates of $2.72 billion. During the same period in the prior year, the firm posted $2.21 EPS. The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. Research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.